Mucosal biology scientific research support component

$251,421UM1FY2013AINIH

Duke University, Durham NC

Investigators

Linked publications & trials

Paper 38562833 Paper 38253617 Paper 38196621 Paper 37873269 Paper 37044090 Paper 36787249 Paper 36443516 Paper 36175869 Paper 36070369 Paper 35087198 Paper 35003053 Paper 34556879 Paper 34549974 Paper 34389622 Paper 34086838 Paper 34019795 Paper 33837212 Paper 33818783 Paper 33798244 Paper 33658386 Paper 33658341 Paper 33562203 Paper 33495459 Paper 33453152 Paper 33214287 Paper 33172842 Paper 33093196 Paper 33072102 Paper 32817216 Paper 32511343 Paper 32402293 Paper 32209668 Paper 32161177 Paper 32156815 Paper 32075963 Paper 32023469 Paper 31980614 Paper 31959979 Paper 31931014 Paper 31841553 Paper 31812703 Paper 31806786 Paper 31748275 Paper 31732530 Paper 31713888 Paper 31559648 Paper 31527908 Paper 31367651 Paper 31308388 Paper 31263112 Paper 31262533 Paper 31217357 Paper 31217249 Paper 31206510 Paper 31153890 Paper 30976531 Paper 30976088 Paper 30974332 Paper 30971821 Paper 30944182 Paper 30737386 Paper 30718403 Paper 30629920 Paper 30552024 Paper 30542158 Paper 30479383 Paper 30429345 Paper 30355496 Paper 30272013 Paper 30270043 Paper 30185554 Paper 30055635 Paper 30021898 Paper 29944756 Paper 29936340 Paper 29915222 Paper 29861171 Paper 29765018 Paper 29739835 Paper 29679388 Paper 29669829 Paper 29636472 Paper 29618643 Paper 29559570 Paper 29549260 Paper 29515029 Paper 29437967 Paper 29395167 Paper 29386288 Paper 29359183 Paper 29326426 Paper 29315059 Paper 29281818 Paper 29266648 Paper 29263306 Paper 29254977 Paper 29248757 Paper 29170366 Paper 29163486 Paper 29150562

Abstract

The primary goal of this Mucosal Biology Scientific Research Support Component (SRSC) is to identify antibody effector functions at mucosal surfaces required to prevent HIV-1 acquisition, define how they differ by route of transmission, and through integrated studies across SRSCs (Mucosal, Vector, Non-human Primate) determine modes of protective antibody induction in non-human primates and in collaborative human clinical vaccine studies. Specific Aims Aim 1. To support CHAVI-ID by defining the functional nature of protective antibody responses at mucosal surfaces elicited in RV144 follow-on trials (RV306, RV328), in other HlV-1 vaccine trials (HVTN 204, 082, 076) and in the HVTN/CHAVI501 mosaic trial. Aim 2. To support CHAVI-ID by assessing the functional characteristics of protective antibodies at mucosal surfaces in NHP Core studies designed to determine optimal route/adjuvant combinations for the induction of mucosal immunity. Aim 3. To support CHAVI-ID by evaluating the functional characteristics of protective antibodies at mucosal surfaces in NHP and Vector SRSC studies designed to determine optimal vector strategies for the induction of mucosal immunity. Aim 4. To support CHAVI-ID by determining the impact of dimeric vs monomeric antibodies on mucosal acquisition.

View original record on NIH RePORTER →